Evidence map›Paper›PMID 27306354›Full record

ReviewDer Urologe. Ausg. A2016

[Social medicine assessment after surgical and targeted treatment of renal cell cancer].

W Vahlensieck, W Hoffmann, D-H Zermann

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

W VahlensieckFachklinik Urologie, Kurpark-Klinik, Kurstr. 41-45, 61231, Bad Nauheim, Deutschland. winfried.vahlensieck@t-online.de.
W HoffmannFachklinik für onkologische Rehabilitation und Anschlussrehabilitation (AHB), Klinik Park-Therme, Badenweiler, Deutschland.
D-H ZermannFachklinik für Urologie, Uroonkologie und Nephrologie, Rehabilitationszentrum Vogtland-Klinik, Bad Elster, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Germany, renal cell cancer counts for 2.5 % of all carcinomas in women and 3.5 % in men. Curative therapy ensures good chances of recovery. But there might be permanent complications like renal insufficiency, pain, incisional hernia, flank muscle relaxation, and paresis. In addition, targeted therapy is associated with several potential side effects. In both therapy groups, severe psychological problems may occur. Still employed patients with these problems must be examined by an expert to estimate the possibilities of returning to working (positive scope of work) and occupations which can not be performed anymore (negative scope of work).

Indexed as

Disability EvaluationCarcinoma, Renal CellFemaleGermanyHumansKidney NeoplasmsMolecular Targeted TherapyNephrectomyPrevalencePsychologyTreatment OutcomePerformance capacityRenal insufficiencyRenal tumor surgeryScope of work, negativeScope of work, positive

Identifiers

PMID27306354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.